Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GUNS
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT04812366 ↗
- Recruiting
- University of British Columbia
- Deep
We haven't built an HCP commentary report on GUNS (apalutamide; apalutamide plus abiraterone plus prednisone; abiraterone plus prednisone in high-risk localized prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GUNS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 23 | |
| YouTube | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide 60mg Tab; Abiraterone Acetate 250mg; Prednisone 5mg Tab; Docetaxel; Niraparib 100mg Oral Capsule; Atezolizumab; Tazemetostat Pill; Capivasertib
- Arms
- Group 1a · Active comparator
- Group 1b · Active comparator
- Group 2a · Active comparator
- Group 2b · Active comparator
- Group 3 · Active comparator
- Group 4 · Active comparator
- Group 5 · Active comparator
- Group 6 · Active comparator
- Enrollment
- 315 (estimated)
- Primary outcomes
- Complete Pathologic Response (pCR)
- Pathological Minimal Residual Disease (pMRD)
- Sponsor
- University of British Columbia with Janssen Inc., University Health Network, Toronto
- Start
- Sep 21, 2021
- Primary completion
- Jun 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04812366 · updated Aug 14, 2026